SG11201704872RA - Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors - Google Patents
Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitorsInfo
- Publication number
- SG11201704872RA SG11201704872RA SG11201704872RA SG11201704872RA SG11201704872RA SG 11201704872R A SG11201704872R A SG 11201704872RA SG 11201704872R A SG11201704872R A SG 11201704872RA SG 11201704872R A SG11201704872R A SG 11201704872RA SG 11201704872R A SG11201704872R A SG 11201704872RA
- Authority
- SG
- Singapore
- Prior art keywords
- trk
- inhibitors
- pharmaceutical formulations
- related kinase
- tropomyosin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462093801P | 2014-12-18 | 2014-12-18 | |
PCT/US2015/066396 WO2016100677A2 (en) | 2014-12-18 | 2015-12-17 | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704872RA true SG11201704872RA (en) | 2017-07-28 |
Family
ID=55080206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704872RA SG11201704872RA (en) | 2014-12-18 | 2015-12-17 | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |
Country Status (22)
Country | Link |
---|---|
US (3) | US10219998B2 (en) |
EP (1) | EP3233057A2 (en) |
JP (1) | JP6606183B2 (en) |
KR (1) | KR102561692B1 (en) |
CN (2) | CN107231803B (en) |
AR (1) | AR103176A1 (en) |
AU (1) | AU2015364557C1 (en) |
BR (1) | BR112017012566B1 (en) |
CA (1) | CA2970938C (en) |
CL (1) | CL2017001543A1 (en) |
CO (1) | CO2017007118A2 (en) |
EA (1) | EA201791336A1 (en) |
IL (1) | IL252901B (en) |
MA (1) | MA40698A3 (en) |
MX (2) | MX2017008058A (en) |
MY (1) | MY195799A (en) |
NZ (1) | NZ733825A (en) |
PH (1) | PH12017501121A1 (en) |
SG (1) | SG11201704872RA (en) |
TN (1) | TN2017000234A1 (en) |
TW (2) | TWI780438B (en) |
WO (1) | WO2016100677A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI731317B (en) | 2013-12-10 | 2021-06-21 | 美商健臻公司 | Tropomyosin-related kinase (trk) inhibitors |
EP3233057A2 (en) | 2014-12-18 | 2017-10-25 | Genzyme Corporation | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |
CN110156813B (en) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | Heterocyclic compounds as TRK inhibitors |
AR114110A1 (en) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | ANTI-TRKA ANTIBODY |
EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
CN114712365B (en) * | 2022-06-07 | 2022-08-23 | 山东绿叶制药有限公司 | Application of TRK inhibitor in preparation of medicament for treating tardive dyskinesia |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4612323A (en) | 1983-06-27 | 1986-09-16 | Sumitomo Chemical Company, Limited | Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole |
JPS60158180A (en) | 1984-01-30 | 1985-08-19 | Sumitomo Chem Co Ltd | Benzimidazole derivative, its preparation, insecticide and acaricide comprising it as active ingredient |
JPS6117569A (en) | 1984-07-03 | 1986-01-25 | Sumitomo Chem Co Ltd | Benzimidazole derivative, its preparation and insecticidal and miticidal agent containing said derivative as active component |
JPS6117569U (en) | 1984-07-05 | 1986-02-01 | エヌオーケー株式会社 | valve device |
JPS61151176A (en) | 1984-12-24 | 1986-07-09 | Sumitomo Chem Co Ltd | Benzimidazole derivative, production thereof, insecticide and acaricide comprising same as active ingredient |
DE4219534A1 (en) | 1992-02-19 | 1993-12-16 | Thomae Gmbh Dr K | Substituted biphenylyl derivatives, pharmaceutical compositions containing them and methods for their preparation |
DK154092D0 (en) | 1992-12-23 | 1992-12-23 | Neurosearch As | IMIDAZOLE COMPOUNDS, THEIR PREPARATION AND USE |
US5702637A (en) | 1995-04-19 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
EP0995742A4 (en) | 1997-06-27 | 2004-08-25 | Fujisawa Pharmaceutical Co | Sulfonamide compounds and medicinal use thereof |
NZ502642A (en) | 1997-07-03 | 2002-06-28 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
US7491748B2 (en) | 2001-08-09 | 2009-02-17 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
GB0122190D0 (en) | 2001-09-14 | 2001-10-31 | Qinetiq Ltd | Novel compounds |
US20040002145A1 (en) | 2002-03-18 | 2004-01-01 | Shewchuk Lisa Marie | Crystal structure of liganded cFMS kinase domain |
EP1505966A4 (en) | 2002-05-10 | 2006-08-30 | Bristol Myers Squibb Co | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
FR2852957B1 (en) | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | NOVEL IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT |
TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
EP1731524A4 (en) | 2004-03-31 | 2009-05-20 | Kissei Pharmaceutical | Phenol derivative, medicinal composition containing the same, and medicinal use thereof |
EA011161B1 (en) | 2004-05-07 | 2009-02-27 | Уорнер-Ламберт Компани Ллс | 3-or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |
CA2587566A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
DK1853588T3 (en) | 2005-02-16 | 2008-09-15 | Astrazeneca Ab | Chemical compounds |
JP2006273879A (en) | 2005-03-25 | 2006-10-12 | Fuji Photo Film Co Ltd | Color display element and method for displaying color |
US7799820B2 (en) | 2005-09-30 | 2010-09-21 | Banyu Pharmaceutical Co., Ltd. | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions |
CN1947717B (en) | 2005-10-14 | 2012-09-26 | 卓敏 | Method for treating neuronal and non-neuronal pain |
EP2139478A4 (en) | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
JP2010524911A (en) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | 5-Aminopyrazol-3-yl-3H-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
EP2183255A4 (en) | 2007-08-29 | 2011-06-15 | Methylgene Inc | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
SI2493895T1 (en) | 2009-10-29 | 2017-10-30 | Vectura Limited | N-containing heteroaryl derivatives as jak3 kinase inhibitors |
RU2012120784A (en) | 2009-11-12 | 2013-12-20 | Селвита С.А. | COMPOUND, METHOD FOR PRODUCING IT, PHARMACEUTICAL COMPOSITION, APPLICATION OF COMPOUND, METHOD FOR MODULATION OR REGULATION OF SERINE / THREONINE KINASES AND MEANS FOR MODULATING SERINE / TREONINES |
US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
US20130165426A1 (en) | 2010-07-06 | 2013-06-27 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
MA35024B1 (en) | 2011-04-05 | 2014-04-03 | Pfizer Ltd | PYRROLO- [2,3-D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES |
EP2791139B1 (en) | 2011-12-12 | 2017-11-08 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
WO2013176970A1 (en) * | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
JP6117569B2 (en) | 2013-02-28 | 2017-04-19 | 三甲株式会社 | Box pallet |
GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
TWI731317B (en) | 2013-12-10 | 2021-06-21 | 美商健臻公司 | Tropomyosin-related kinase (trk) inhibitors |
EP3233057A2 (en) | 2014-12-18 | 2017-10-25 | Genzyme Corporation | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |
CN107197528B (en) | 2016-03-14 | 2020-12-25 | 华为技术有限公司 | Method and device for scheduling and allocating resources |
-
2015
- 2015-12-17 EP EP15823088.8A patent/EP3233057A2/en active Pending
- 2015-12-17 SG SG11201704872RA patent/SG11201704872RA/en unknown
- 2015-12-17 CA CA2970938A patent/CA2970938C/en active Active
- 2015-12-17 CN CN201580076248.9A patent/CN107231803B/en active Active
- 2015-12-17 JP JP2017532722A patent/JP6606183B2/en active Active
- 2015-12-17 WO PCT/US2015/066396 patent/WO2016100677A2/en active Application Filing
- 2015-12-17 US US15/536,544 patent/US10219998B2/en active Active
- 2015-12-17 EA EA201791336A patent/EA201791336A1/en unknown
- 2015-12-17 MA MA40698A patent/MA40698A3/en unknown
- 2015-12-17 NZ NZ733825A patent/NZ733825A/en unknown
- 2015-12-17 AU AU2015364557A patent/AU2015364557C1/en active Active
- 2015-12-17 MX MX2017008058A patent/MX2017008058A/en unknown
- 2015-12-17 MY MYPI2017702037A patent/MY195799A/en unknown
- 2015-12-17 TN TN2017000234A patent/TN2017000234A1/en unknown
- 2015-12-17 TW TW109118415A patent/TWI780438B/en active
- 2015-12-17 TW TW104142525A patent/TWI696621B/en active
- 2015-12-17 CN CN201911088940.XA patent/CN110950862B/en active Active
- 2015-12-17 KR KR1020177019802A patent/KR102561692B1/en active IP Right Grant
- 2015-12-17 BR BR112017012566-8A patent/BR112017012566B1/en active IP Right Grant
- 2015-12-18 AR ARP150104196A patent/AR103176A1/en unknown
-
2017
- 2017-06-14 IL IL252901A patent/IL252901B/en active IP Right Grant
- 2017-06-14 CL CL2017001543A patent/CL2017001543A1/en unknown
- 2017-06-15 PH PH12017501121A patent/PH12017501121A1/en unknown
- 2017-06-16 MX MX2020013015A patent/MX2020013015A/en unknown
- 2017-07-17 CO CONC2017/0007118A patent/CO2017007118A2/en unknown
-
2019
- 2019-01-04 US US16/239,904 patent/US11110055B2/en active Active
-
2021
- 2021-08-20 US US17/407,419 patent/US11793749B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190039T1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
HUS2400003I1 (en) | Compounds useful as kinase inhibitors | |
HK1245260A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
ZA201700115B (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
EP3247692A4 (en) | Inhibitors of trka kinase | |
PL3218378T3 (en) | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | |
HK1244704A1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
IL252901B (en) | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors | |
IL264593A (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors | |
IL258438B (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors | |
EP3361250A4 (en) | Pharmaceutical composition for inducing exercise-like effects | |
IL267279A (en) | Pharmaceutical formulations of suvorexant | |
SG11201608123VA (en) | Pharmaceutical composition for external use | |
SG11201608124XA (en) | Pharmaceutical composition for external use | |
HK1244703A1 (en) | Pharmaceutical composition containing imidazoline derivative | |
GB201522245D0 (en) | Compounds useful as kinase inhibitors | |
AU2015904223A0 (en) | Novel kinase inhibitors i | |
GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
SG11201608122PA (en) | Pharmaceutical composition for external use |